drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00001 | DB06603 | 1,578 | 39 | [
"DDInter1037",
"DDInter1387"
] | Lepirudin | Panobinostat | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1578,
25,
39
]
],
[
[
1578,
24,
578
],
[
578,
63,
39
]
],
[
[
1578,
24,
599
],
[
599,
24,
39
]
],
[
[
1578,
25,
4
],
[
4,
24,
... | [
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor... | Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemt... |
DB01263 | DB09049 | 859 | 1,135 | [
"DDInter1494",
"DDInter1261"
] | Posaconazole | Naloxegol | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Major | 2 | [
[
[
859,
25,
1135
]
],
[
[
859,
25,
1406
],
[
1406,
62,
1135
]
],
[
[
859,
63,
1424
],
[
1424,
23,
1135
]
],
[
[
859,
25,
1069
],
[
1069,
... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} ... | Posaconazole may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a minor... |
DB00872 | DB12332 | 1,080 | 1,619 | [
"DDInter438",
"DDInter1626"
] | Conivaptan | Rucaparib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1080,
24,
1619
]
],
[
[
1080,
24,
222
],
[
222,
23,
1619
]
],
[
[
1080,
25,
1135
],
[
1135,
23,
1619
]
],
[
[
1080,
24,
309
],
[
309,
... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Conivaptan may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a m... |
DB00434 | DB01142 | 13 | 1,264 | [
"DDInter459",
"DDInter593"
] | Cyproheptadine | Doxepin | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
13,
24,
1264
]
],
[
[
13,
63,
508
],
[
508,
24,
1264
]
],
[
[
13,
24,
401
],
[
401,
24,
1264
]
],
[
[
13,
40,
11305
],
[
11305,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and P... |
DB00359 | DB01309 | 161 | 1,254 | [
"DDInter1721",
"DDInter933"
] | Sulfadiazine | Insulin glulisine | One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
161,
24,
1254
]
],
[
[
161,
1,
1247
],
[
1247,
24,
1254
]
],
[
[
161,
63,
305
],
[
305,
24,
1254
]
],
[
[
161,
24,
590
],
[
590,
... | [
[
[
"Sulfadiazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Sulfadiazine",
"{u} (Compound) resembles {v} (Compound)",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"... | Sulfadiazine (Compound) resembles Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Sulfadiazine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase... |
DB01403 | DB09065 | 9 | 760 | [
"DDInter1175",
"DDInter424"
] | Methotrimeprazine | Cobicistat | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
9,
24,
760
]
],
[
[
9,
24,
1374
],
[
1374,
23,
760
]
],
[
[
9,
25,
868
],
[
868,
24,
760
]
],
[
[
9,
24,
761
],
[
761,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
... | Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Methotrimeprazine may lead to a major life threatening interaction when taken with Vemurafenib and Vemura... |
DB06626 | DB11652 | 263 | 1,155 | [
"DDInter147",
"DDInter1891"
] | Axitinib | Tucatinib | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
263,
25,
1155
]
],
[
[
263,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
263,
64,
609
],
[
609,
24,
1155
]
],
[
[
263,
63,
522
],
[
522,
... | [
[
[
"Axitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
... | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Axitinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause... |
DB04868 | DB06077 | 478 | 879 | [
"DDInter1293",
"DDInter1102"
] | Nilotinib | Lumateperone | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
478,
24,
879
]
],
[
[
478,
24,
214
],
[
214,
63,
879
]
],
[
[
478,
64,
392
],
[
392,
24,
879
]
],
[
[
478,
63,
597
],
[
597,
24,... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Nilotinib may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may caus... |
DB01278 | DB01577 | 1,021 | 1,529 | [
"DDInter1506",
"DDInter1161"
] | Pramlintide | Metamfetamine | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Moderate | 1 | [
[
[
1021,
24,
1529
]
],
[
[
1021,
63,
939
],
[
939,
40,
1529
]
],
[
[
1021,
24,
22
],
[
22,
24,
1529
]
],
[
[
1021,
63,
1039
],
[
1039,
... | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzphetamine"
],
... | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction t... |
DB00584 | DB06779 | 610 | 365 | [
"DDInter638",
"DDInter470"
] | Enalapril | Dalteparin | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Moderate | 1 | [
[
[
610,
24,
365
]
],
[
[
610,
1,
954
],
[
954,
24,
365
]
],
[
[
610,
63,
305
],
[
305,
24,
365
]
],
[
[
610,
40,
743
],
[
743,
24,
... | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate in... | Enalapril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause... |
DB01246 | DB05294 | 820 | 1,069 | [
"DDInter45",
"DDInter1917"
] | Alimemazine | Vandetanib | A phenothiazine derivative that is used as an antipruritic. | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
820,
25,
1069
]
],
[
[
820,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
820,
21,
29282
],
[
29282,
60,
1069
]
],
[
[
820,
62,
1247
],
[
1247,... | [
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vande... | Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Alimemazine (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Vandetanib (Compound)
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole... |
DB08938 | DB12147 | 1,384 | 241 | [
"DDInter1112",
"DDInter661"
] | Magaldrate | Erdafitinib | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Major | 2 | [
[
[
1384,
25,
241
]
],
[
[
1384,
63,
478
],
[
478,
24,
241
]
],
[
[
1384,
62,
1220
],
[
1220,
25,
241
]
],
[
[
1384,
63,
1040
],
[
1040,
... | [
[
[
"Magaldrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib"... | Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Magaldrate may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexame... |
DB00687 | DB01344 | 870 | 1,231 | [
"DDInter747",
"DDInter1830"
] | Fludrocortisone | Tolevamer | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Moderate | 1 | [
[
[
870,
24,
1231
]
],
[
[
870,
24,
519
],
[
519,
24,
1231
]
],
[
[
870,
24,
961
],
[
961,
63,
1231
]
],
[
[
870,
1,
1486
],
[
1486,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paliperidone"
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Licorice... |
DB00655 | DB08820 | 559 | 1,478 | [
"DDInter682",
"DDInter997"
] | Estrone | Ivacaftor | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
559,
24,
1478
]
],
[
[
559,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
559,
21,
28762
],
[
28762,
60,
1478
]
],
[
[
559,
24,
1411
],
[
1411,... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Estrone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Estrone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ivacaftor (Compound)
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may ... |
DB00445 | DB00459 | 322 | 640 | [
"DDInter655",
"DDInter21"
] | Epirubicin | Acitretin | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Moderate | 1 | [
[
[
322,
24,
640
]
],
[
[
322,
24,
1517
],
[
1517,
64,
640
]
],
[
[
322,
21,
29333
],
[
29333,
60,
640
]
],
[
[
322,
24,
637
],
[
637,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acitretin"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Acitretin
Epirubicin (Compound) causes Optic neuritis (Side Effect) and Optic neuritis (Side Effect) is caused by Acitretin (Compound)... |
DB08868 | DB08903 | 1,011 | 996 | [
"DDInter737",
"DDInter170"
] | Fingolimod | Bedaquiline | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
1011,
25,
996
]
],
[
[
1011,
6,
8374
],
[
8374,
45,
996
]
],
[
[
1011,
21,
29267
],
[
29267,
60,
996
]
],
[
[
1011,
62,
112
],
[
112,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Fingolimod",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaqu... | Fingolimod (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Fingolimod (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Bedaquiline (Compound)
Fingolimod may cause a minor interaction that can limit cl... |
DB00364 | DB00881 | 417 | 954 | [
"DDInter1717",
"DDInter1554"
] | Sucralfate | Quinapril | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Moderate | 1 | [
[
[
417,
24,
954
]
],
[
[
417,
23,
1523
],
[
1523,
40,
954
]
],
[
[
417,
21,
28845
],
[
28845,
60,
954
]
],
[
[
417,
24,
1117
],
[
1117,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Labetalol"
],
[
... | Sucralfate may cause a minor interaction that can limit clinical effects when taken with Labetalol and Labetalol (Compound) resembles Quinapril (Compound)
Sucralfate (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Quinapril (Compound)
Sucralfate may cause a moderate interaction that could e... |
DB00365 | DB00448 | 839 | 1,215 | [
"DDInter842",
"DDInter1022"
] | Grepafloxacin | Lansoprazole | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Moderate | 1 | [
[
[
839,
24,
1215
]
],
[
[
839,
24,
263
],
[
263,
62,
1215
]
],
[
[
839,
25,
1069
],
[
1069,
62,
1215
]
],
[
[
839,
63,
1031
],
[
1031,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
],
... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Lansoprazole
Grepafloxacin may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may caus... |
DB01619 | DB04953 | 830 | 495 | [
"DDInter1441",
"DDInter708"
] | Phenindamine | Ezogabine | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
830,
24,
495
]
],
[
[
830,
63,
662
],
[
662,
24,
495
]
],
[
[
830,
24,
1609
],
[
1609,
63,
495
]
],
[
[
830,
1,
1219
],
[
1219,
... | [
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverin... |
DB00704 | DB08881 | 267 | 868 | [
"DDInter1263",
"DDInter1925"
] | Naltrexone | Vemurafenib | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
267,
24,
868
]
],
[
[
267,
18,
8386
],
[
8386,
46,
868
]
],
[
[
267,
7,
3932
],
[
3932,
46,
868
]
],
[
[
267,
18,
4303
],
[
4303,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Naltrexone",
"{u} (Compound) downregulates {v} (Gene)",
"MTHFD2"
],
[
"MTHFD2",
"{u} (Gene) is upregulated by {... | Naltrexone (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Vemurafenib (Compound)
Naltrexone (Compound) upregulates FOXO3 (Gene) and FOXO3 (Gene) is upregulated by Vemurafenib (Compound)
Naltrexone (Compound) downregulates CLTB (Gene) and CLTB (Gene) is downregulated by Vemurafenib (Compound)... |
DB00341 | DB00555 | 1,242 | 706 | [
"DDInter343",
"DDInter1020"
] | Cetirizine | Lamotrigine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It... | Moderate | 1 | [
[
[
1242,
24,
706
]
],
[
[
1242,
21,
29291
],
[
29291,
60,
706
]
],
[
[
1242,
24,
530
],
[
530,
24,
706
]
],
[
[
1242,
24,
100
],
[
100,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lamotrigine"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Muscular weakness"
],
[
"Muscular weakness",
"{u} (Sid... | Cetirizine (Compound) causes Muscular weakness (Side Effect) and Muscular weakness (Side Effect) is caused by Lamotrigine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when t... |
DB00242 | DB11978 | 1,064 | 124 | [
"DDInter392",
"DDInter822"
] | Cladribine | Glasdegib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
1064,
24,
124
]
],
[
[
1064,
24,
466
],
[
466,
62,
124
]
],
[
[
1064,
24,
1612
],
[
1612,
24,
124
]
],
[
[
1064,
25,
629
],
[
629,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fost... |
DB00405 | DB00697 | 128 | 876 | [
"DDInter517",
"DDInter1821"
] | Dexbrompheniramine | Tizanidine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Moderate | 1 | [
[
[
128,
24,
876
]
],
[
[
128,
24,
1617
],
[
1617,
1,
876
]
],
[
[
128,
24,
401
],
[
401,
63,
876
]
],
[
[
128,
24,
19
],
[
19,
24,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidi... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Tizanidine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moder... |
DB01211 | DB01253 | 609 | 628 | [
"DDInter393",
"DDInter664"
] | Clarithromycin | Ergometrine | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Major | 2 | [
[
[
609,
25,
628
]
],
[
[
609,
64,
1131
],
[
1131,
40,
628
]
],
[
[
609,
63,
469
],
[
469,
40,
628
]
],
[
[
609,
6,
8374
],
[
8374,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ergometrine"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methysergide"
],
[
"Methysergide",... | Clarithromycin may lead to a major life threatening interaction when taken with Methysergide and Methysergide (Compound) resembles Ergometrine (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine and Bromocriptine (Compound) resembles Ergometrine (Compo... |
DB01069 | DB01208 | 401 | 945 | [
"DDInter1533",
"DDInter1705"
] | Promethazine | Sparfloxacin | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
401,
25,
945
]
],
[
[
401,
63,
739
],
[
739,
1,
945
]
],
[
[
401,
64,
1176
],
[
1176,
1,
945
]
],
[
[
401,
24,
1539
],
[
1539,
1... | [
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
[
"Lo... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Promethazine may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)... |
DB09065 | DB13879 | 760 | 1,043 | [
"DDInter424",
"DDInter824"
] | Cobicistat | Glecaprevir | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic ba... | Moderate | 1 | [
[
[
760,
24,
1043
]
],
[
[
760,
64,
1135
],
[
1135,
23,
1043
]
],
[
[
760,
24,
466
],
[
466,
24,
1043
]
],
[
[
760,
64,
594
],
[
594,
... | [
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glecaprevir"
]
],
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol"... | Cobicistat may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glecaprevir
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause... |
DB00808 | DB01164 | 1,605 | 803 | [
"DDInter916",
"DDInter272"
] | Indapamide | Calcium chloride | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Calcium chloride is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in ... | Moderate | 1 | [
[
[
1605,
24,
803
]
],
[
[
1605,
21,
29196
],
[
29196,
60,
803
]
],
[
[
1605,
62,
1545
],
[
1545,
24,
803
]
],
[
[
1605,
40,
811
],
[
811,... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium chloride"
]
],
[
[
"Indapamide",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Eff... | Indapamide (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Calcium chloride (Compound)
Indapamide may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline and Oxytetracycline may cause a moderate interaction that could exacerbate diseases whe... |
DB00078 | DB00086 | 1,172 | 1,167 | [
"DDInter898",
"DDInter1712"
] | Ibritumomab tiuxetan | Streptokinase | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Major | 2 | [
[
[
1172,
25,
1167
]
],
[
[
1172,
23,
539
],
[
539,
62,
1167
]
],
[
[
1172,
25,
831
],
[
831,
63,
1167
]
],
[
[
1172,
24,
1230
],
[
1230,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptokinase"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
... | Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Streptokinase
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Indomethacin and Indo... |
DB00095 | DB00305 | 66 | 377 | [
"DDInter623",
"DDInter1232"
] | Efalizumab | Mitomycin | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Moderate | 1 | [
[
[
66,
24,
377
]
],
[
[
66,
24,
450
],
[
450,
63,
377
]
],
[
[
66,
24,
552
],
[
552,
24,
377
]
],
[
[
66,
63,
58
],
[
58,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Carmustine... |
DB00285 | DB09330 | 1,100 | 985 | [
"DDInter1927",
"DDInter1352"
] | Venlafaxine | Osimertinib | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1100,
25,
985
]
],
[
[
1100,
23,
112
],
[
112,
23,
985
]
],
[
[
1100,
24,
1478
],
[
1478,
24,
985
]
],
[
[
1100,
24,
657
],
[
657,
... | [
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Venlafaxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Iv... |
DB00373 | DB08946 | 461 | 512 | [
"DDInter1809",
"DDInter962"
] | Timolol | Iopanoic acid | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Iopanoic acid contains iodine and is useful as a contrast medium in cholecystography. | Moderate | 1 | [
[
[
461,
24,
512
]
],
[
[
461,
24,
1106
],
[
1106,
24,
512
]
],
[
[
461,
24,
777
],
[
777,
63,
512
]
],
[
[
461,
1,
668
],
[
668,
24... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopanoic acid"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
],... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Gadofosveset trisodium and Gadofosveset trisodium may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid
Timolol may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00350 | DB06691 | 1,214 | 849 | [
"DDInter1226",
"DDInter1155"
] | Minoxidil | Mepyramine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1214,
24,
849
]
],
[
[
1214,
24,
358
],
[
358,
24,
849
]
],
[
[
1214,
63,
1648
],
[
1648,
24,
849
]
],
[
[
1214,
24,
407
],
[
407,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Ald... |
DB06791 | DB13074 | 1,446 | 877 | [
"DDInter1021",
"DDInter1110"
] | Lanreotide | Macimorelin | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
1446,
24,
877
]
],
[
[
1446,
63,
176
],
[
176,
24,
877
]
],
[
[
1446,
24,
1296
],
[
1296,
24,
877
]
],
[
[
1446,
24,
1375
],
[
1375,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
... | Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Insulin ... |
DB08890 | DB11057 | 16 | 720 | [
"DDInter1069",
"DDInter1223"
] | Linaclotide | Mineral oil | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin deri... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Minor | 0 | [
[
[
16,
23,
720
]
],
[
[
16,
23,
338
],
[
338,
63,
720
]
],
[
[
16,
62,
355
],
[
355,
24,
720
]
],
[
[
16,
23,
338
],
[
338,
63,
... | [
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mineral oil"
]
],
[
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Docusate"
],
[
... | Linaclotide may cause a minor interaction that can limit clinical effects when taken with Docusate and Docusate may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Linaclotide may cause a minor interaction that can limit clinical effects when taken with Lactulose and Lactulose ma... |
DB00352 | DB00978 | 482 | 739 | [
"DDInter1814",
"DDInter1084"
] | Tioguanine | Lomefloxacin | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Minor | 0 | [
[
[
482,
23,
739
]
],
[
[
482,
23,
945
],
[
945,
40,
739
]
],
[
[
482,
63,
1176
],
[
1176,
1,
739
]
],
[
[
482,
23,
1299
],
[
1299,
... | [
[
[
"Tioguanine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Tioguanine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
... | Tioguanine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Lomefloxacin (... |
DB00307 | DB00401 | 1,101 | 84 | [
"DDInter202",
"DDInter1298"
] | Bexarotene | Nisoldipine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Moderate | 1 | [
[
[
1101,
24,
84
]
],
[
[
1101,
24,
854
],
[
854,
1,
84
]
],
[
[
1101,
24,
376
],
[
376,
40,
84
]
],
[
[
1101,
63,
1428
],
[
1428,
1... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nisoldipine"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nimodipine"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Nimodipine and Nimodipine (Compound) resembles Nisoldipine (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine and Amlodipine (Compound) resembles Nisoldipine (Compound... |
DB00532 | DB00741 | 208 | 167 | [
"DDInter1152",
"DDInter885"
] | Mephenytoin | Hydrocortisone | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
208,
24,
167
]
],
[
[
208,
24,
1220
],
[
1220,
40,
167
]
],
[
[
208,
24,
870
],
[
870,
1,
167
]
],
[
[
208,
63,
251
],
[
251,
40... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles ... |
DB00390 | DB08907 | 1,252 | 1,344 | [
"DDInter554",
"DDInter280"
] | Digoxin | Canagliflozin | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1252,
24,
1344
]
],
[
[
1252,
6,
4973
],
[
4973,
45,
1344
]
],
[
[
1252,
21,
28680
],
[
28680,
60,
1344
]
],
[
[
1252,
24,
1033
],
[
1... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Digoxin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Canagliflozin (Compound)
Digoxin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Canagliflozin (Compound)
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause ... |
DB01125 | DB01250 | 279 | 712 | [
"DDInter98",
"DDInter1334"
] | Anisindione | Olsalazine | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inf... | Minor | 0 | [
[
[
279,
23,
712
]
],
[
[
279,
64,
50
],
[
50,
40,
712
]
],
[
[
279,
76,
1274
],
[
1274,
24,
712
]
],
[
[
279,
63,
1411
],
[
1411,
2... | [
[
[
"Anisindione",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Olsalazine"
]
],
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfasalazine"
],
[
"Sulfasa... | Anisindione may lead to a major life threatening interaction when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Olsalazine (Compound)
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Anisindione may lead to a major life threatening interactio... |
DB00683 | DB01156 | 1,382 | 593 | [
"DDInter1212",
"DDInter252"
] | Midazolam | Bupropion | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
1382,
24,
593
]
],
[
[
1382,
6,
8374
],
[
8374,
45,
593
]
],
[
[
1382,
21,
29243
],
[
29243,
60,
593
]
],
[
[
1382,
63,
752
],
[
752,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Midazolam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Midazolam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Midazolam (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Bupropion (Compound)
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine ... |
DB00960 | DB09038 | 887 | 1,450 | [
"DDInter1471",
"DDInter636"
] | Pindolol | Empagliflozin | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
887,
24,
1450
]
],
[
[
887,
25,
659
],
[
659,
63,
1450
]
],
[
[
887,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
887,
24,
885
],
[
885,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Pindolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
],
[
"Vilanterol"... | Pindolol may lead to a major life threatening interaction when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cau... |
DB00696 | DB01105 | 826 | 222 | [
"DDInter665",
"DDInter1665"
] | Ergotamine | Sibutramine | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Major | 2 | [
[
[
826,
25,
222
]
],
[
[
826,
6,
8374
],
[
8374,
45,
222
]
],
[
[
826,
21,
28748
],
[
28748,
60,
222
]
],
[
[
826,
25,
384
],
[
384,
... | [
[
[
"Ergotamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Ergotamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sibutr... | Ergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Ergotamine (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Sibutramine (Compound)
Ergotamine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause ... |
DB00888 | DB12674 | 1,001 | 975 | [
"DDInter1133",
"DDInter1105"
] | Mechlorethamine | Lurbinectedin | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
1001,
24,
975
]
],
[
[
1001,
24,
1532
],
[
1532,
24,
975
]
],
[
[
1001,
63,
147
],
[
147,
24,
975
]
],
[
[
1001,
40,
450
],
[
450,
... | [
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Mechlorethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
... | Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Vinblast... |
DB00196 | DB04951 | 600 | 187 | [
"DDInter743",
"DDInter1477"
] | Fluconazole | Pirfenidone | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Moderate | 1 | [
[
[
600,
24,
187
]
],
[
[
600,
25,
1670
],
[
1670,
63,
187
]
],
[
[
600,
24,
637
],
[
637,
63,
187
]
],
[
[
600,
25,
463
],
[
463,
2... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglus... | Fluconazole may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi... |
DB00305 | DB11988 | 377 | 270 | [
"DDInter1232",
"DDInter1321"
] | Mitomycin | Ocrelizumab | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
377,
24,
270
]
],
[
[
377,
63,
1461
],
[
1461,
23,
270
]
],
[
[
377,
24,
134
],
[
134,
24,
270
]
],
[
[
377,
24,
287
],
[
287,
6... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbin... |
DB00215 | DB01619 | 1,230 | 830 | [
"DDInter388",
"DDInter1441"
] | Citalopram | Phenindamine | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1230,
24,
830
]
],
[
[
1230,
24,
537
],
[
537,
40,
830
]
],
[
[
1230,
24,
13
],
[
13,
24,
830
]
],
[
[
1230,
24,
104
],
[
104,
1... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction th... |
DB00727 | DB06292 | 685 | 549 | [
"DDInter1304",
"DDInter474"
] | Nitroglycerin | Dapagliflozin | Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate and a vasodilating agent that was first discovered in 1847. Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced headaches in factory workers while workers with angina pectoris or heart failure ex... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
685,
24,
549
]
],
[
[
685,
24,
1344
],
[
1344,
40,
549
]
],
[
[
685,
21,
28882
],
[
28882,
60,
549
]
],
[
[
685,
24,
401
],
[
401,
... | [
[
[
"Nitroglycerin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Nitroglycerin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
... | Nitroglycerin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Nitroglycerin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dapagliflozin (Co... |
DB00781 | DB01336 | 1,481 | 545 | [
"DDInter1489",
"DDInter1198"
] | Polymyxin B | Metocurine | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine. | Major | 2 | [
[
[
1481,
25,
545
]
],
[
[
1481,
25,
1217
],
[
1217,
40,
545
]
],
[
[
1481,
63,
91
],
[
91,
24,
545
]
],
[
[
1481,
1,
1441
],
[
1441,
... | [
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metocurine"
]
],
[
[
"Polymyxin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tubocurarine"
],
[
"Tubocurarine",
... | Polymyxin B may lead to a major life threatening interaction when taken with Tubocurarine and Tubocurarine (Compound) resembles Metocurine (Compound)
Polymyxin B may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerba... |
DB00026 | DB09312 | 1,184 | 967 | [
"DDInter94",
"DDInter106"
] | Anakinra | Antithymocyte immunoglobulin (rabbit) | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin i... | Moderate | 1 | [
[
[
1184,
24,
967
]
],
[
[
1184,
23,
1193
],
[
1193,
62,
967
]
],
[
[
1184,
24,
1683
],
[
1683,
24,
967
]
],
[
[
1184,
24,
1531
],
[
1531,... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antilymphocyte immunoglobulin (horse)"
]
],
[
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc g... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Antilymphocyte immunoglobulin (horse)
Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken... |
DB00262 | DB00495 | 552 | 139 | [
"DDInter302",
"DDInter1961"
] | Carmustine | Zidovudine | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Moderate | 1 | [
[
[
552,
24,
139
]
],
[
[
552,
21,
28662
],
[
28662,
60,
139
]
],
[
[
552,
25,
752
],
[
752,
62,
139
]
],
[
[
552,
24,
810
],
[
810,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Carmustine",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by ... | Carmustine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Zidovudine (Compound)
Carmustine may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Zidovudine
Carmustine may caus... |
DB00816 | DB04861 | 1,674 | 1,592 | [
"DDInter1346",
"DDInter1271"
] | Orciprenaline | Nebivolol | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Moderate | 1 | [
[
[
1674,
24,
1592
]
],
[
[
1674,
6,
3576
],
[
3576,
45,
1592
]
],
[
[
1674,
21,
28762
],
[
28762,
60,
1592
]
],
[
[
1674,
24,
1450
],
[
1... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Orciprenaline",
"{u} (Compound) binds {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is bound by {v} (Compound... | Orciprenaline (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Nebivolol (Compound)
Orciprenaline (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nebivolol (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin an... |
DB00196 | DB09082 | 600 | 659 | [
"DDInter743",
"DDInter1934"
] | Fluconazole | Vilanterol | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
600,
24,
659
]
],
[
[
600,
24,
1220
],
[
1220,
23,
659
]
],
[
[
600,
24,
1570
],
[
1570,
24,
659
]
],
[
[
600,
25,
927
],
[
927,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin an... |
DB00008 | DB00022 | 491 | 268 | [
"DDInter1407",
"DDInter1408"
] | Peginterferon alfa-2a | Peginterferon alfa-2b | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Moderate | 1 | [
[
[
491,
24,
268
]
],
[
[
491,
23,
450
],
[
450,
62,
268
]
],
[
[
491,
24,
1480
],
[
1480,
63,
268
]
],
[
[
491,
23,
576
],
[
576,
6... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
... | Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Peginterferon alfa-2b
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate disea... |
DB00549 | DB12674 | 522 | 975 | [
"DDInter1955",
"DDInter1105"
] | Zafirlukast | Lurbinectedin | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
522,
24,
975
]
],
[
[
522,
24,
1488
],
[
1488,
24,
975
]
],
[
[
522,
24,
159
],
[
159,
63,
975
]
],
[
[
522,
63,
589
],
[
589,
2... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib ... |
DB00302 | DB00603 | 335 | 303 | [
"DDInter1844",
"DDInter1137"
] | Tranexamic acid | Medroxyprogesterone acetate | Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. It was first patented in 1957 and received its initial US approval in 1986. | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Major | 2 | [
[
[
335,
25,
303
]
],
[
[
335,
21,
28997
],
[
28997,
60,
303
]
],
[
[
335,
25,
888
],
[
888,
62,
303
]
],
[
[
335,
21,
28997
],
[
28997,
... | [
[
[
"Tranexamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Tranexamic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder"... | Tranexamic acid (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Medroxyprogesterone acetate (Compound)
Tranexamic acid may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a minor interaction that can limit clinical e... |
DB01253 | DB09054 | 628 | 384 | [
"DDInter664",
"DDInter905"
] | Ergometrine | Idelalisib | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
628,
25,
384
]
],
[
[
628,
63,
600
],
[
600,
24,
384
]
],
[
[
628,
24,
868
],
[
868,
24,
384
]
],
[
[
628,
24,
412
],
[
412,
63,... | [
[
[
"Ergometrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Flucona... | Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and V... |
DB00524 | DB00544 | 811 | 970 | [
"DDInter1199",
"DDInter757"
] | Metolazone | Fluorouracil | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Moderate | 1 | [
[
[
811,
24,
970
]
],
[
[
811,
21,
28719
],
[
28719,
60,
970
]
],
[
[
811,
40,
1014
],
[
1014,
63,
970
]
],
[
[
811,
63,
1648
],
[
1648,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v... | Metolazone (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Fluorouracil (Compound)
Metolazone (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil
Metolazone may cause a moderate interaction th... |
DB00467 | DB00631 | 1,467 | 372 | [
"DDInter644",
"DDInter405"
] | Enoxacin | Clofarabine | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Minor | 0 | [
[
[
1467,
23,
372
]
],
[
[
1467,
23,
1488
],
[
1488,
40,
372
]
],
[
[
1467,
6,
3199
],
[
3199,
57,
372
]
],
[
[
1467,
1,
956
],
[
956,
... | [
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clofarabine"
]
],
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fludarabine"
],
[
"F... | Enoxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine and Fludarabine (Compound) resembles Clofarabine (Compound)
Enoxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Clofarabine (Compound)
Enoxacin (Compound) resembles Norfloxacin (Compound) and Norfl... |
DB00758 | DB00912 | 1,347 | 473 | [
"DDInter413",
"DDInter1581"
] | Clopidogrel | Repaglinide | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Major | 2 | [
[
[
1347,
25,
473
]
],
[
[
1347,
6,
3486
],
[
3486,
45,
473
]
],
[
[
1347,
21,
28873
],
[
28873,
60,
473
]
],
[
[
1347,
63,
311
],
[
311,
... | [
[
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Repaglinide"
]
],
[
[
"Clopidogrel",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Repa... | Clopidogrel (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Clopidogrel (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Valdecox... |
DB00461 | DB06081 | 598 | 1,046 | [
"DDInter1254",
"DDInter286"
] | Nabumetone | Caplacizumab | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Moderate | 1 | [
[
[
598,
24,
1046
]
],
[
[
598,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
598,
63,
1061
],
[
1061,
24,
1046
]
],
[
[
598,
24,
738
],
[
738,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Treprosti... |
DB00501 | DB06636 | 752 | 1,623 | [
"DDInter380",
"DDInter980"
] | Cimetidine | Isavuconazonium | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
752,
24,
1623
]
],
[
[
752,
23,
466
],
[
466,
62,
1623
]
],
[
[
752,
23,
222
],
[
222,
23,
1623
]
],
[
[
752,
24,
1419
],
[
1419,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Si... |
DB01166 | DB01218 | 477 | 1,493 | [
"DDInter379",
"DDInter852"
] | Cilostazol | Halofantrine | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
477,
25,
1493
]
],
[
[
477,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
477,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
477,
63,
479
],
[
479,... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Cilostazol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Halof... | Cilostazol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Cilostazol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Cilostazol may cause a moderate interaction that could exacerbate diseases when ta... |
DB01036 | DB01278 | 211 | 1,021 | [
"DDInter1832",
"DDInter1506"
] | Tolterodine | Pramlintide | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
211,
24,
1021
]
],
[
[
211,
63,
1507
],
[
1507,
24,
1021
]
],
[
[
211,
24,
609
],
[
609,
24,
1021
]
],
[
[
211,
24,
98
],
[
98,
... | [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
... | Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin a... |
DB01166 | DB06717 | 477 | 875 | [
"DDInter379",
"DDInter778"
] | Cilostazol | Fosaprepitant | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Major | 2 | [
[
[
477,
25,
875
]
],
[
[
477,
64,
723
],
[
723,
1,
875
]
],
[
[
477,
21,
29340
],
[
29340,
60,
875
]
],
[
[
477,
63,
222
],
[
222,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u... | Cilostazol may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Cilostazol (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Fosaprepitant (Compound)
Cilostazol may cause a ... |
DB00196 | DB00489 | 600 | 17 | [
"DDInter743",
"DDInter1704"
] | Fluconazole | Sotalol | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Major | 2 | [
[
[
600,
25,
17
]
],
[
[
600,
25,
347
],
[
347,
40,
17
]
],
[
[
600,
21,
28719
],
[
28719,
60,
17
]
],
[
[
600,
24,
578
],
[
578,
62... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} (Com... | Fluconazole may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide (Compound) resembles Sotalol (Compound)
Fluconazole (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Sotalol (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases... |
DB00280 | DB09133 | 494 | 1,527 | [
"DDInter575",
"DDInter965"
] | Disopyramide | Iothalamic acid | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Moderate | 1 | [
[
[
494,
24,
1527
]
],
[
[
494,
24,
589
],
[
589,
25,
1527
]
],
[
[
494,
25,
485
],
[
485,
25,
1527
]
],
[
[
494,
24,
589
],
[
589,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Iothalamic acid
Disopyramide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to a ma... |
DB00398 | DB08816 | 79 | 578 | [
"DDInter1702",
"DDInter1802"
] | Sorafenib | Ticagrelor | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
79,
24,
578
]
],
[
[
79,
6,
4973
],
[
4973,
45,
578
]
],
[
[
79,
21,
28646
],
[
28646,
60,
578
]
],
[
[
79,
25,
17
],
[
17,
23,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Sorafenib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Sorafenib (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Sorafenib may lead to a majo... |
DB00106 | DB08868 | 618 | 1,011 | [
"DDInter4",
"DDInter737"
] | Abarelix | Fingolimod | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
618,
25,
1011
]
],
[
[
618,
23,
1247
],
[
1247,
23,
1011
]
],
[
[
618,
24,
144
],
[
144,
63,
1011
]
],
[
[
618,
24,
867
],
[
867,
... | [
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfametho... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Ol... |
DB00215 | DB13074 | 1,230 | 877 | [
"DDInter388",
"DDInter1110"
] | Citalopram | Macimorelin | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1230,
25,
877
]
],
[
[
1230,
23,
112
],
[
112,
23,
877
]
],
[
[
1230,
24,
1479
],
[
1479,
24,
877
]
],
[
[
1230,
25,
913
],
[
913,
... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Citalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic ac... |
DB00653 | DB01344 | 544 | 1,231 | [
"DDInter1120",
"DDInter1830"
] | Magnesium sulfate | Tolevamer | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Moderate | 1 | [
[
[
544,
24,
1231
]
],
[
[
544,
24,
1473
],
[
1473,
63,
1231
]
],
[
[
544,
24,
1486
],
[
1486,
24,
1231
]
],
[
[
544,
63,
1573
],
[
1573,
... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluc... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when t... |
DB00445 | DB00472 | 322 | 758 | [
"DDInter655",
"DDInter758"
] | Epirubicin | Fluoxetine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Moderate | 1 | [
[
[
322,
24,
758
]
],
[
[
322,
63,
847
],
[
847,
1,
758
]
],
[
[
322,
24,
109
],
[
109,
40,
758
]
],
[
[
322,
7,
8606
],
[
8606,
46,... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Fluoxetine (Compound)
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) resembles Fluoxetine (Compound... |
DB00393 | DB00757 | 854 | 1,166 | [
"DDInter1295",
"DDInter581"
] | Nimodipine | Dolasetron | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
854,
25,
1166
]
],
[
[
854,
6,
8374
],
[
8374,
45,
1166
]
],
[
[
854,
21,
28803
],
[
28803,
60,
1166
]
],
[
[
854,
24,
752
],
[
752,
... | [
[
[
"Nimodipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Nimodipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dolaset... | Nimodipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dolasetron (Compound)
Nimodipine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Dolasetron (Compound)
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidi... |
DB00231 | DB09293 | 1,174 | 116 | [
"DDInter1761",
"DDInter954"
] | Temazepam | Iodide I-131 | Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chem... | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Moderate | 1 | [
[
[
1174,
24,
116
]
],
[
[
1174,
24,
701
],
[
701,
24,
116
]
],
[
[
1174,
1,
1418
],
[
1418,
24,
116
]
],
[
[
1174,
40,
1382
],
[
1382,
... | [
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Temazepam (Compound) resembles Estazolam (Compound) and Estazolam may cause a moderate interaction that could e... |
DB00741 | DB01319 | 167 | 34 | [
"DDInter885",
"DDInter777"
] | Hydrocortisone | Fosamprenavir | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
167,
24,
34
]
],
[
[
167,
63,
1091
],
[
1091,
40,
34
]
],
[
[
167,
6,
8374
],
[
8374,
45,
34
]
],
[
[
167,
21,
28723
],
[
28723,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Hydrocortisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Hydrocortisone (Compound) causes Malnutrition (Side ... |
DB06782 | DB13257 | 1,575 | 260 | [
"DDInter563",
"DDInter727"
] | Dimercaprol | Ferrous sulfate anhydrous | Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II. It was developed as an experimental antidote against the arsenic-based poison gas Lewisite. It has been used clinically since 1949 in arsenic, cadmium and mercury poisoning. In addition, it has in the... | Iron deficiency anemia is a large public health concern worldwide, especially in young children, infants, and women of childbearing age. This type of anemia occurs when iron intake, iron stores, and iron loss do not adequately support the formation of erythrocytes, also known as red blood cells. Ferrous sulfate is a sy... | Major | 2 | [
[
[
1575,
25,
260
]
],
[
[
1575,
25,
489
],
[
489,
24,
260
]
],
[
[
1575,
64,
1596
],
[
1596,
23,
1114
],
[
1114,
23,
260
]
],
[
[
1575,
... | [
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ferrous sulfate anhydrous"
]
],
[
[
"Dimercaprol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iron sucrose"
],
[
"Iron s... | Dimercaprol may lead to a major life threatening interaction when taken with Iron sucrose and Iron sucrose may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous
Dimercaprol may lead to a major life threatening interaction when taken with Iron and Iron may cause a mino... |
DB01067 | DB08882 | 959 | 1,281 | [
"DDInter826",
"DDInter1070"
] | Glipizide | Linagliptin | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
959,
24,
1281
]
],
[
[
959,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
959,
5,
11640
],
[
11640,
44,
1281
]
],
[
[
959,
6,
8374
],
[
8374,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Glipizide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Linagliptin (Compound)
Glipizide (Compound) ... |
DB00619 | DB11921 | 1,419 | 1,019 | [
"DDInter909",
"DDInter492"
] | Imatinib | Deflazacort | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
1419,
25,
1019
]
],
[
[
1419,
24,
192
],
[
192,
24,
1019
]
],
[
[
1419,
24,
270
],
[
270,
63,
1019
]
],
[
[
1419,
63,
1428
],
[
1428,
... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
],
[
"Est... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens and Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ocre... |
DB00213 | DB09263 | 837 | 1,436 | [
"DDInter1388",
"DDInter1399"
] | Pantoprazole | Patiromer | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Moderate | 1 | [
[
[
837,
24,
1436
]
],
[
[
837,
1,
660
],
[
660,
24,
1436
]
],
[
[
837,
24,
428
],
[
428,
63,
1436
]
],
[
[
837,
24,
1152
],
[
1152,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a ... | Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a moderate int... |
DB00945 | DB14276 | 1,479 | 1,631 | [
"DDInter20",
"DDInter1892"
] | Acetylsalicylic acid | Turmeric | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
1479,
23,
1631
]
],
[
[
1479,
63,
20
],
[
20,
23,
1631
]
],
[
[
1479,
25,
500
],
[
500,
23,
1631
]
],
[
[
1479,
64,
553
],
[
553,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplas... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Acetylsalicylic acid may lead to a major life threatening interaction when taken with Enoxaparin and E... |
DB00341 | DB01403 | 1,242 | 9 | [
"DDInter343",
"DDInter1175"
] | Cetirizine | Methotrimeprazine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
1242,
24,
9
]
],
[
[
1242,
24,
1178
],
[
1178,
40,
9
]
],
[
[
1242,
24,
1164
],
[
1164,
1,
9
]
],
[
[
1242,
24,
401
],
[
401,
24... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles M... |
DB00222 | DB01155 | 245 | 872 | [
"DDInter825",
"DDInter813"
] | Glimepiride | Gemifloxacin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Major | 2 | [
[
[
245,
25,
872
]
],
[
[
245,
25,
739
],
[
739,
1,
872
]
],
[
[
245,
25,
945
],
[
945,
40,
872
]
],
[
[
245,
64,
1176
],
[
1176,
1,... | [
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
... | Glimepiride may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Glimepiride may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (Compound)
Glimepiride may ... |
DB01268 | DB12887 | 1,151 | 1,598 | [
"DDInter1731",
"DDInter1750"
] | Sunitinib | Tazemetostat | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
1151,
24,
1598
]
],
[
[
1151,
24,
594
],
[
594,
24,
1598
]
],
[
[
1151,
25,
985
],
[
985,
24,
1598
]
],
[
[
1151,
63,
888
],
[
888,
... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Sunitinib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause ... |
DB00352 | DB11986 | 482 | 484 | [
"DDInter1814",
"DDInter648"
] | Tioguanine | Entrectinib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
482,
24,
484
]
],
[
[
482,
24,
1247
],
[
1247,
23,
484
]
],
[
[
482,
23,
1539
],
[
1539,
24,
484
]
],
[
[
482,
24,
998
],
[
998,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
],
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Tioguanine may cause a minor interaction that can limit clinical effects when taken with Ofloxacin an... |
DB00686 | DB04932 | 383 | 1,564 | [
"DDInter1424",
"DDInter491"
] | Pentosan polysulfate | Defibrotide | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Moderate | 1 | [
[
[
383,
24,
1564
]
],
[
[
383,
24,
714
],
[
714,
24,
1564
]
],
[
[
383,
24,
1496
],
[
1496,
63,
1564
]
],
[
[
383,
63,
1061
],
[
1061,
... | [
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ilopro... | Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Nint... |
DB01259 | DB09104 | 392 | 286 | [
"DDInter1024",
"DDInter1118"
] | Lapatinib | Magnesium hydroxide | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
392,
24,
286
]
],
[
[
392,
24,
481
],
[
481,
23,
286
]
],
[
[
392,
63,
820
],
[
820,
23,
286
]
],
[
[
392,
64,
1252
],
[
1252,
2... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
],
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alim... |
DB00031 | DB00722 | 20 | 743 | [
"DDInter1764",
"DDInter1079"
] | Tenecteplase | Lisinopril | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Moderate | 1 | [
[
[
20,
24,
743
]
],
[
[
20,
24,
610
],
[
610,
40,
743
]
],
[
[
20,
24,
1638
],
[
1638,
1,
743
]
],
[
[
20,
25,
500
],
[
500,
63,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisinopril"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Lisinopril (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Lisinopril (Comp... |
DB01035 | DB01142 | 1,401 | 1,264 | [
"DDInter1524",
"DDInter593"
] | Procainamide | Doxepin | A derivative of procaine with less CNS action. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
1401,
25,
1264
]
],
[
[
1401,
25,
401
],
[
401,
24,
1264
]
],
[
[
1401,
6,
4304
],
[
4304,
45,
1264
]
],
[
[
1401,
21,
29209
],
[
2920... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"... | Procainamide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Procainamide (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Doxepin (Compound)
Procainamide (Compound) causes An... |
DB00491 | DB00863 | 127 | 1,194 | [
"DDInter1217",
"DDInter1568"
] | Miglitol | Ranitidine | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Minor | 0 | [
[
[
127,
23,
1194
]
],
[
[
127,
21,
28722
],
[
28722,
60,
1194
]
],
[
[
127,
63,
798
],
[
798,
23,
1194
]
],
[
[
127,
24,
1664
],
[
1664,
... | [
[
[
"Miglitol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
]
],
[
[
"Miglitol",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (C... | Miglitol (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Ranitidine (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Ranitidine
Miglitol... |
DB00496 | DB00835 | 194 | 100 | [
"DDInter480",
"DDInter245"
] | Darifenacin | Brompheniramine | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
194,
24,
100
]
],
[
[
194,
24,
832
],
[
832,
24,
100
]
],
[
[
194,
63,
128
],
[
128,
24,
100
]
],
[
[
194,
6,
8374
],
[
8374,
45... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Dexbro... |
DB00083 | DB01176 | 677 | 537 | [
"DDInter225",
"DDInter453"
] | Botulinum toxin type A | Cyclizine | In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperf... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
677,
24,
537
]
],
[
[
677,
24,
1511
],
[
1511,
63,
537
]
],
[
[
677,
24,
104
],
[
104,
1,
537
]
],
[
[
677,
24,
13
],
[
13,
24,
... | [
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepe... | Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00762 | DB11817 | 613 | 1,259 | [
"DDInter973",
"DDInter165"
] | Irinotecan | Baricitinib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
613,
25,
1259
]
],
[
[
613,
63,
1461
],
[
1461,
23,
1259
]
],
[
[
613,
24,
949
],
[
949,
24,
1259
]
],
[
[
613,
24,
1129
],
[
1129,
... | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoi... |
DB00983 | DB11730 | 480 | 351 | [
"DDInter776",
"DDInter1588"
] | Formoterol | Ribociclib | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
480,
25,
351
]
],
[
[
480,
24,
222
],
[
222,
23,
351
]
],
[
[
480,
63,
867
],
[
867,
24,
351
]
],
[
[
480,
62,
1486
],
[
1486,
2... | [
[
[
"Formoterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Olanzapine and Olanza... |
DB00261 | DB00564 | 702 | 1,236 | [
"DDInter93",
"DDInter293"
] | Anagrelide | Carbamazepine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
702,
24,
1236
]
],
[
[
702,
24,
1405
],
[
1405,
40,
1236
]
],
[
[
702,
25,
508
],
[
508,
1,
1236
]
],
[
[
702,
25,
820
],
[
820,
... | [
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Carbamazepine (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Promazine and Promazine (Compound) resembles Carbamazepine (Compound)
A... |
DB06636 | DB12941 | 1,623 | 466 | [
"DDInter980",
"DDInter481"
] | Isavuconazonium | Darolutamide | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
1623,
23,
466
]
],
[
[
1623,
63,
600
],
[
600,
23,
466
]
],
[
[
1623,
24,
351
],
[
351,
23,
466
]
],
[
[
1623,
25,
484
],
[
484,
... | [
[
[
"Isavuconazonium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
... | Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Ribocicli... |
DB01128 | DB09104 | 918 | 286 | [
"DDInter204",
"DDInter1118"
] | Bicalutamide | Magnesium hydroxide | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
918,
24,
286
]
],
[
[
918,
24,
820
],
[
820,
23,
286
]
],
[
[
918,
63,
401
],
[
401,
23,
286
]
],
[
[
918,
24,
859
],
[
859,
24,... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Prometha... |
DB00978 | DB09407 | 739 | 853 | [
"DDInter1084",
"DDInter1114"
] | Lomefloxacin | Magnesium chloride | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
739,
24,
853
]
],
[
[
739,
1,
1539
],
[
1539,
24,
853
]
],
[
[
739,
63,
544
],
[
544,
24,
853
]
],
[
[
739,
24,
460
],
[
460,
63... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause... | Lomefloxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderat... |
DB01036 | DB01069 | 211 | 401 | [
"DDInter1832",
"DDInter1533"
] | Tolterodine | Promethazine | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
211,
24,
401
]
],
[
[
211,
24,
1264
],
[
1264,
63,
401
]
],
[
[
211,
63,
104
],
[
104,
24,
401
]
],
[
[
211,
6,
4304
],
[
4304,
... | [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdi... |
DB01006 | DB04951 | 300 | 187 | [
"DDInter1040",
"DDInter1477"
] | Letrozole | Pirfenidone | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Moderate | 1 | [
[
[
300,
24,
187
]
],
[
[
300,
24,
535
],
[
535,
24,
187
]
],
[
[
300,
24,
1017
],
[
1017,
63,
187
]
],
[
[
300,
63,
932
],
[
932,
2... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pirfenidone"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenofibrate"
],
[
... | Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Fenofibrate and Fenofibrate may cause a moderate interaction that could exacerbate diseases when taken with Pirfenidone
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorla... |
DB00814 | DB01276 | 1,171 | 123 | [
"DDInter1143",
"DDInter706"
] | Meloxicam | Exenatide | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1171,
24,
123
]
],
[
[
1171,
63,
1573
],
[
1573,
24,
123
]
],
[
[
1171,
24,
1039
],
[
1039,
24,
123
]
],
[
[
1171,
24,
1040
],
[
1040,... | [
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexf... |
DB00014 | DB00734 | 521 | 1,664 | [
"DDInter839",
"DDInter1605"
] | Goserelin | Risperidone | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
521,
24,
1664
]
],
[
[
521,
25,
924
],
[
924,
40,
1664
]
],
[
[
521,
24,
519
],
[
519,
40,
1664
]
],
[
[
521,
21,
28787
],
[
28787,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidon... | Goserelin may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Risperidone (Compound)
Goserelin... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.